UC Davis CCC receives first SPORE grant for immunotherapy in head and neck cancer

UC Davis study: TB vaccine shrinks liver cancer tumors in mice

A UC Davis Health study found that a single dose of Bacillus Calmette-Guérin, or BCG, the vaccine for tuberculosis, reduced liver tumor burden and extended the survival of mice with liver cancer. The study, published in Advanced Science, is the first to show the promising effects of the vaccine in treating liver cancer.

March 08, 2024

Vol.50 No.10

Clinical Roundup

Community cancer care linked with poorer outcomes for some head/neck cancers

Care for patients with human papillomavirus (HPV)-related squamous cell cancers of the oropharynx (an area in back of the throat) is shifting toward community cancer centers, but patients treated in this setting may be less likely to survive, according to new research by investigators from the Johns Hopkins Kimmel Cancer Center and its Head and Neck Cancer Center.

January 05, 2024

Vol.50 No.01

Clinical Roundup

Novel liquid biopsy of lymph fluid could guide precision treatment for head and neck cancer

Researchers from University of Pittsburgh and Washington University School of Medicine in St. Louis found that liquid from surgical drains, which is usually tossed in the trash, could inform more precise treatments for patients with head and neck cancer caused by human papillomavirus.

January 05, 2024

Vol.50 No.01

In Brief

Angela Yoon named director of MUSC Hollings Cancer Center Biorepository and Tissue Analysis Shared Resource

Angela J. Yoon was named director of the MUSC Hollings Cancer Center Biorepository and Tissue Analysis Shared Resource, effective Dec. 1; she will oversee a growing collection of cancer-associated biospecimens that allow researchers to translate Biological discoveries into prevention, diagnosis and treatment of cancer.

December 08, 2023

Vol.49 No.45

Drugs & Targets

FDA approves Loqtorz for nasopharyngeal carcinoma

FDA has approved Loqtorz (toripalimab-tpzi) with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma.

November 03, 2023

Vol.49 No.41

Clinical Roundup

UC Davis researchers identify “switch” to activate cancer cell death

A research team from the UC Davis Comprehensive Cancer Center has identified a crucial epitope (a protein section that can activate the larger protein) on the CD95 receptor that can cause cells to die.

October 27, 2023

Vol.49 No.40

UC Davis CCC receives first SPORE grant for immunotherapy in head and neck cancer

YOU MAY BE INTERESTED IN

UC Davis study: TB vaccine shrinks liver cancer tumors in mice

Community cancer care linked with poorer outcomes for some head/neck cancers

Novel liquid biopsy of lymph fluid could guide precision treatment for head and neck cancer

Angela Yoon named director of MUSC Hollings Cancer Center Biorepository and Tissue Analysis Shared Resource

FDA approves Loqtorz for nasopharyngeal carcinoma

UC Davis researchers identify “switch” to activate cancer cell death

Renew today!

Subscriber content

Login